# Minoxidil for persistent chemotherapy- and endocrine-therapy hair loss

Source: https://onco.cc/technologies/minoxidil-chemotherapy-alopecia/  
OnCo record `minoxidil-chemotherapy-alopecia` (Technology). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

Most hair grows back after chemotherapy, but a minority, especially after docetaxel, are left with thin hair, and tamoxifen and aromatase inhibitors cause gradual thinning. Minoxidil lotion or low-dose tablets, the same treatment used for pattern hair loss, improved regrowth in most patients in dermatology series and shortened regrowth time in an early randomised trial.

## Summary

Minoxidil is a potassium-channel opener that prolongs the growth (anagen) phase of hair follicles; topical 2 percent and 5 percent formulations are licensed for androgenetic alopecia and low-dose oral minoxidil (0.25 to 5 mg) is prescribed off-label for the same purpose. In a randomised placebo-controlled trial of 22 women receiving doxorubicin-cyclophosphamide chemotherapy (Duvic et al., 1996), topical 2 percent minoxidil did not prevent hair loss but shortened the time to maximal regrowth by about 50 days. For persistent chemotherapy-induced alopecia, most often after docetaxel or after busulfan conditioning for transplant, and for endocrine-therapy-induced alopecia, the Memorial Sloan Kettering dermatology group reported that topical minoxidil produced moderate or significant improvement in around 80 percent of treated patients with endocrine-related hair thinning (Freites-Martinez et al., JAMA Dermatology 2018), and case series of low-dose oral minoxidil describe similar regrowth. There are no large randomised trials in these settings. Side effects are scalp irritation, unwanted facial hair, and with tablets fluid retention, palpitations and low blood pressure; it should be prescribed by a clinician aware of the patient's cardiac history.

## Fields

- Kind: Technology
- Status: emerging
- Last checked: 2026-09-10
- Tags: complementary; supportive-care; evidence:moderate
- Principle: Opening ATP-sensitive potassium channels increases follicular blood flow and growth-factor signalling, extending anagen and enlarging miniaturised follicles.
- Strengths: Widely available, inexpensive; Consistent regrowth in dermatology series; Randomised evidence for faster regrowth after chemotherapy
- Limitations: No large randomised trial in cancer-related alopecia; Does not prevent chemotherapy hair loss; Cardiovascular side effects with oral dosing

## Sources

- Wikipedia: https://en.wikipedia.org/wiki/Minoxidil
- A randomised trial of minoxidil in chemotherapy-induced alopecia (J Am Acad Dermatol 1996): https://doi.org/10.1016/s0190-9622(96)90500-9
- Endocrine therapy-induced alopecia in patients with breast cancer (JAMA Dermatol 2018): https://doi.org/10.1001/jamadermatol.2018.0454
- Hair disorders in cancer survivors (J Am Acad Dermatol 2019): https://doi.org/10.1016/j.jaad.2018.03.056

## Connected records

- ideas: [Fund scalp cooling and hair-preserving measures for every alopecia-inducing regimen](https://onco.cc/ideas/idea-moon-hair-preservation-for-all/)
- technologies: [Antiandrogens for hair: spironolactone, finasteride, dutasteride](https://onco.cc/technologies/hair-antiandrogens-alopecia/), [Bimatoprost for eyelash and eyebrow regrowth](https://onco.cc/technologies/bimatoprost-eyelash-regrowth/), [Camouflage and restoration: fibres, micropigmentation, transplantation](https://onco.cc/technologies/hair-camouflage-and-restoration/), [Creams and lotions tried to prevent chemotherapy hair loss](https://onco.cc/technologies/hair-topical-prevention-agents/), [Cytotoxic chemotherapy](https://onco.cc/technologies/cytotoxic-chemotherapy/), [Endocrine therapy (SERMs, AIs, SERDs)](https://onco.cc/technologies/endocrine-therapy/), [Low-level light therapy (photobiomodulation) for hair](https://onco.cc/technologies/hair-photobiomodulation/), [Platelet-rich plasma for hair after cancer treatment](https://onco.cc/technologies/hair-platelet-rich-plasma/), [Platelet-rich plasma for survivors](https://onco.cc/technologies/rejuv-frontier-platelet-rich-plasma/), [Scalp cooling (cold caps: DigniCap, Paxman)](https://onco.cc/technologies/scalp-cooling/), [Supplements sold for hair growth after cancer treatment](https://onco.cc/technologies/hair-supplements-marketed/), [Wigs, cranial prostheses and head coverings](https://onco.cc/technologies/wigs-cranial-prosthesis/)
- cancers: [HR-positive / HER2-negative breast cancer](https://onco.cc/cancers/breast-hr-positive/), [Triple-negative breast cancer (TNBC)](https://onco.cc/cancers/tnbc/)
- fronts: [Chemotherapy](https://onco.cc/fronts/chemotherapy/), [Hormonal Therapy](https://onco.cc/fronts/hormonal/), [Recovery & Rejuvenation](https://onco.cc/fronts/rejuvenation/), [Supportive Care & Survivorship](https://onco.cc/fronts/supportive-care/)
- drugs: [Cyclophosphamide](https://onco.cc/drugs/cyclophosphamide/), [Docetaxel](https://onco.cc/drugs/docetaxel/), [Doxorubicin](https://onco.cc/drugs/doxorubicin/), [Exemestane](https://onco.cc/drugs/exemestane/), [Letrozole (and other aromatase inhibitors)](https://onco.cc/drugs/letrozole/), [Tamoxifen](https://onco.cc/drugs/tamoxifen/)
- institutions: [Memorial Sloan Kettering Cancer Center](https://onco.cc/institutions/mskcc/)
- terms: [Anagen effluvium (chemotherapy hair loss)](https://onco.cc/terms/hair-anagen-effluvium/), [Aromatase inhibitor](https://onco.cc/terms/aromatase-inhibitor/), [Endocrine-therapy-induced alopecia](https://onco.cc/terms/alopecia-endocrine-therapy/), [Late effects and survivorship toxicity](https://onco.cc/terms/late-effects/), [Persistent chemotherapy-induced alopecia](https://onco.cc/terms/alopecia-persistent-chemotherapy/), [Persistent radiation-induced alopecia](https://onco.cc/terms/alopecia-radiotherapy-persistent/), [Regrowth after chemotherapy (chemo curls)](https://onco.cc/terms/hair-regrowth-after-chemotherapy/)
- bottlenecks: [Survivorship and late effects are neglected](https://onco.cc/bottlenecks/b-survivorship/), [Toxicity and quality of life are undervalued](https://onco.cc/bottlenecks/b-toxicity-qol/)
- key papers: [A randomized trial of minoxidil in chemotherapy-induced alopecia](https://onco.cc/key-papers/paper-duvic-j-am-acad-dermatol/), [Endocrine Therapy-Induced Alopecia in Patients With Breast Cancer](https://onco.cc/key-papers/paper-freites-martinez-jama-dermatol/), [Hair disorders in cancer survivors](https://onco.cc/key-papers/paper-freites-martinez-j-am-acad-dermatol/)
- roadmaps: [Supportive care and survivorship roadmap: making treatment bearable → proving it extends life → caring for tens of millions afterwards](https://onco.cc/roadmaps/survivorship-roadmap/)

---
JSON: https://onco.cc/api/v1/entities/minoxidil-chemotherapy-alopecia.json